-
公开(公告)号：US10940113B2
公开(公告)日：2021-03-09
申请号：US15901968
申请日：2018-02-22
Inventor： Chih-Chiang Yang , Wen-Che Wang , Chiao-Ling Hsu
IPC: A61K9/20 , A61K9/28 , A61K31/196 , A61K31/606
Abstract: A pharmaceutical composition for colon targeting, a method for treating a colon-related disease using the same and a preparation method thereof are disclosed. The pharmaceutical composition of the present disclosure comprises: a core matrix comprising a cross-linked hydrogel and an active ingredient, wherein the active ingredient is dispersed in the cross-linked hydrogel, and a content of the active ingredient is 65 wt % to 95 wt % based on a total weight of the core matrix.
-
公开(公告)号：US20190388340A1
公开(公告)日：2019-12-26
申请号：US16446634
申请日：2019-06-20
Applicant: Center Laboratories, Inc. , Medical and Pharmaceutical Industry Technology and Development Center
Inventor： Meng-Ju LEE , Shu-Hsien CHANG , Chih-Chiang YANG , Yuan-Chih LE , Tse-Ching LIN , Ko-Chiang CHEN , Lai-Cheng CHIN , Tai-Yin KE , Pei-Ying LIAO
IPC: A61K9/00 , A61K31/13 , A61K31/445 , A61K9/48
Abstract: Disclosed herein is an oral dosage formulation suitable for treating a neurodegenerative disorder. The oral dosage formulation contains both sustained-release and immediate-release drugs. The sustained-release drug in the oral dosage formulation is memantine, and the immediate-release drug in the oral dosage formulation is donepezil and/or memantine, and the formulation is characterized in having a pH-independent dissolution profile of memantine at a pH range from about 1.0 to about 7.0.
-
公开(公告)号：US20180243220A1
公开(公告)日：2018-08-30
申请号：US15901968
申请日：2018-02-22
Inventor： Chih-Chiang YANG , Wen-Che WANG , Chiao-Ling HSU
IPC: A61K9/20 , A61K31/196 , A61K9/28
CPC classification number: A61K9/205 , A61K9/2846 , A61K9/2893 , A61K31/196 , A61K31/606
Abstract: A pharmaceutical composition for colon targeting, a method for treating a colon-related disease using the same and a preparation method thereof are disclosed. The pharmaceutical composition of the present disclosure comprises: a core matrix comprising a cross-linked hydrogel and an active ingredient, wherein the active ingredient is dispersed in the cross-linked hydrogel, and a content of the active ingredient is 65 wt % to 95 wt % based on a total weight of the core matrix.
-
公开(公告)号：US20140314867A1
公开(公告)日：2014-10-23
申请号：US14258860
申请日：2014-04-22
Inventor： Shu-Wen Whu , Chung-Chih Cheng , Chih-Chiang Yang
IPC: A61K9/16 , A61K31/122
CPC classification number: A61K9/1647 , A61K31/122
Abstract: A vitamin K2 microsphere. The microsphere includes a poly(lactide-co-glycolide) acid (PLGA) particle, in which the Mw of PLGA is between 1000 and 300000, and the molar ratio between the lactide repeat units and the glycolide repeate unit is 1-9:9-1; and one or more vitamin K2 molecules are embedded in the PLGA particle, wherein the vitamin K2 is present in an amount of 0.005-75 wt %, based on the weight of the microsphere. Also disclosed are a method of preparing the vitamin K2 microsphere, a method of treating osteoporosis using this microsphere, and a pharmaceutical composition containing the microsphere.
Abstract translation: 维生素K2微球。 微球包括聚（丙交酯 - 共 - 乙交酯）酸（PLGA）颗粒，其中PLGA的Mw为1000至300000，丙交酯重复单元与乙交酯重复单元之间的摩尔比为1-9:9 -1; 并且一种或多种维生素K2分子嵌入PLGA颗粒中，其中基于微球的重量，维生素K2以0.005-75重量％的量存在。 还公开了制备维生素K2微球的方法，使用该微球治疗骨质疏松症的方法和含有微球的药物组合物。
-
5.发明授权公开(公告)号：US11759471B2
公开(公告)日：2023-09-19
申请号：US16845695
申请日：2020-04-10
Inventor： Shih-Ku Lin , Chih-Chiang Yang , Tse-Ching Lin , Lai-Cheng Chin , Pei Hsuan Ho
IPC: A61K31/554 , A61K31/5513 , A61K31/551 , A61K9/28 , A61K31/519 , A61K31/496 , A61K31/38
CPC classification number: A61K31/554 , A61K9/28 , A61K31/38 , A61K31/496 , A61K31/519 , A61K31/551 , A61K31/5513
Abstract: The present invention is concerned with a modified release pharmaceutical composition comprising an effective amount of at least one antipsychotic agent so that the antipsychotic agent(s) are released in such a manner to better accord with physiological and chronotherapeutic requirements of patients.
-
Patent Agency Ranking
公开(公告)号：US20200375901A1
公开(公告)日：2020-12-03
申请号：US16887259
申请日：2020-05-29
Inventor： Meng-Kun TSAI , Chih-Chiang YANG , Wen-Che WANG , Tzu-Yu CHIEN , Chien-Chia WU , Lai-Cheng CHIN
IPC: A61K9/16 , A61K9/00 , A61K31/436 , A61K31/717
Abstract: An oral composition includes an immediate-release pharmaceutical admixture and an extended-release pharmaceutical admixture. The immediate-release pharmaceutical admixture includes a first portion of an active ingredient and a first portion of a hydrophilic dispersant, in which the active ingredient is substantially insoluble in water. The extended-release pharmaceutical admixture includes a controlled-release material, a second portion of the active ingredient, and a second portion of the hydrophilic dispersant, wherein the second portion of the active ingredient and the second portion of the hydrophilic dispersant are mixed in the controlled-release material, wherein the active ingredient is present as a nanoparticle in the immediate-release pharmaceutical admixture and the extended-release pharmaceutical admixture.
-
7.发明申请CONTROLLED RELEASE PHARMACEUTICAL COMPOSITION AND METHOD FOR MANUFACTURING THE SAME 审中-公开控制释放的药物组合物及其制造方法公开(公告)号：US20160317454A1
公开(公告)日：2016-11-03
申请号：US14826328
申请日：2015-08-14
Inventor： Chih-Chiang YANG , Yuan-Chih LE , Yu-Liang LIN , Yi-Ming LIOU
IPC: A61K9/50 , A61K9/48 , A61K31/403
CPC classification number: A61K9/5042 , A61K9/5026 , A61K9/5078 , A61K9/5089 , A61K31/403
Abstract: A controlled release pharmaceutical composition is disclosed, which comprises: a drug core comprising 10-50 mg of Carvedilol or a pharmaceutical acceptable salt thereof, and a first pharmaceutical acceptable polymer, wherein a content of the first pharmaceutical acceptable polymer is 0.01-50% based on a total weight of the drug core; and a controlled release coating layer covering the drug core and comprising a second pharmaceutical acceptable polymer. In addition, a method for manufacturing the aforementioned controlled release pharmaceutical composition is also disclosed.
Abstract translation: 公开了一种控释药物组合物，其包含：包含10-50mg卡维地洛或其药学上可接受的盐的药物核心和第一药学上可接受的聚合物，其中第一药学上可接受的聚合物的含量为0.01-50％ 药物核心总重量; 以及覆盖药物核心并包含第二药学上可接受的聚合物的控释层。 此外，还公开了制造上述控释药物组合物的方法。
-
公开(公告)号：US20150283194A1
公开(公告)日：2015-10-08
申请号：US14436332
申请日：2013-12-18
Inventor： Jui-Ching Chen , Che-Yi Lin , Yu-Hsiang Huang , Ming-Yu Chao , Chih-Sheng Hung
IPC: A61K36/28 , A61K31/485
CPC classification number: A61K36/28 , A61K31/485 , A61K2236/00
Abstract: Disclosed herein is the use of an extract from an Aster species for the preparation of a medicament for the treatment of pain. The extract is extracted from fresh and/or dried roots and rhizomes of a Tatarian aster (Aster tartaricus) plant, in which the extraction is performed by use of water or 10-95% (v/v) ethanol as an extractant to obtain an extraction mixture. In some embodiments, the extraction mixture is further subject to column chromatography, in which the cloumn was eluted in sequence with water, and at least one eluent other than water.
Abstract translation: 本文公开了使用来自Aster物质的提取物来制备用于治疗疼痛的药物。 提取物是从新鲜和/或干燥的根状和根状茎中提取的，其中通过使用水或10-95％（v / v）乙醇作为萃取剂进行提取，从而得到一种 提取混合物。 在一些实施方案中，萃取混合物进一步进行柱色谱法，其中色谱柱依次用水和至少一种除水以外的洗脱液洗脱。
-
公开(公告)号：US20150224159A1
公开(公告)日：2015-08-13
申请号：US14613065
申请日：2015-02-03
Inventor： Leah Lo , Win-Chin Chiang , Jui-Ching Chen , Yu-Min Lin , Chien-Chang Wu , Che-Yi Lin , Chien-Jen Shih , Yu-Hsuan Lin , Tzu-Chun Chen , Yu-Hsiang Huang
IPC: A61K36/535 , A61K31/352 , A61K31/216
CPC classification number: A61K36/535 , A61K31/216 , A61K31/352 , A61K2236/00 , A61K2300/00
Abstract: Disclosed is an extract of Perilla frutescens seeds that contains rosmarinic acid, luteolin, and apigenin, the weight ratio between rosmarinic acid, luteolin, and apigenin being 0.1-200:0.1-200:1. Also disclosed is a method for treating a psychiatric disorder using the above-described extract or an extract of Perilla frutescens seeds containing at least an active agent selected from the group consisting of rosmarinic acid, luteolin, and apigenin.
Abstract translation: 公开了含有迷迭香酸，木犀草素和芹菜素的紫苏属种子提取物，迷迭香酸，木犀草素和芹菜素的重量比为0.1-200：0.1〜200：1。 还公开了使用上述提取物或含有至少一种选自迷迭香酸，木犀草素和芹菜素的活性剂的紫苏属种子提取物治疗精神病的方法。
-
公开(公告)号：US10894023B2
公开(公告)日：2021-01-19
申请号：US16446634
申请日：2019-06-20
Applicant: Center Laboratories, Inc. , Medical and Pharmaceutical Industry Technology and Development Center
Inventor： Meng-Ju Lee , Shu-Hsien Chang , Chih-Chiang Yang , Yuan-Chih Le , Tse-Ching Lin , Ko-Chiang Chen , Lai-Cheng Chin , Tai-Yin Ke , Pei-Ying Liao
IPC: A61K31/13 , A61K31/445 , A61K9/16 , A61K9/50 , A61K9/48 , A61K9/00 , A61P25/16 , A61P25/14 , A61P25/28
Abstract: Disclosed herein is an oral dosage formulation suitable for treating a neurodegenerative disorder. The oral dosage formulation contains both sustained-release and immediate-release drugs. The sustained-release drug in the oral dosage formulation is memantine, and the immediate-release drug in the oral dosage formulation is donepezil and/or memantine, and the formulation is characterized in having a pH-independent dissolution profile of memantine at a pH range from about 1.0 to about 7.0.
-
-
-
-
-
-
-
-
-
Search Results
14
records
(took 0.02 seconds)
